{"nctId":"NCT01871558","briefTitle":"Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin","startDateStruct":{"date":"2013-06"},"conditions":["Type 2 Diabetes Mellitus (T2DM)"],"count":42,"armGroups":[{"label":"SU+metformin + Basal Insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin","Drug: sulfonylurea (SU)","Drug: Basal Insulin"]},{"label":"Metformin/vildagliptin + Basal Insulin","type":"EXPERIMENTAL","interventionNames":["Drug: Vildagliptin","Drug: Metformin","Drug: Basal Insulin"]}],"interventions":[{"name":"Vildagliptin","otherNames":["Galvus"]},{"name":"Metformin","otherNames":[]},{"name":"sulfonylurea (SU)","otherNames":[]},{"name":"Basal Insulin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* T2DM patients inadequately controlled with metformin+ SU combination therapy at max tolerated doses and in whom the decision to start basal insulin has been taken\n* with stable metformin+ SU combination therapy for at least 12 weeks prior to randomization\n* with a glycemic target of HbA1c \\<= 7%\n* with HbA1c at inclusion \\>7% and \\<=9%\n* Patients willing and able to start basal insulin and perform appropriate self monitoring of blood glucose (SMBG)\n\nExclusion Criteria:\n\n* contraindication for either SUs, metformin or insulin and history of hypersensitivity to vildagliptin\n* acute or chronic diseases that interfere with efficacy/safety results of this trial or put patient at risk\n\nOther protocol defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Who Reported at Least One Symptomatic Hypoglycemic Event During the 24 Week Randomized Period in Both Treatment Arms","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"45.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Reaching Their Glycemic Target Without Hypoglycemic Events","description":"Glycemic target is defined as Glycated hemoglobin(HbA1c) ≤ 7%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c to Week 24 in Both Treatment Arms","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"0.56"},{"groupId":"OG001","value":"8.2","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"0.71"},{"groupId":"OG001","value":"7.4","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight in Both Treatment Arms","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.51"},{"groupId":"OG001","value":"1.4","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Mean Daily Insulin Dose at Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":"23.08"},{"groupId":"OG001","value":"19.8","spread":"13.83"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Severe and Confirmed Hypoglycemic Events","description":"Severe hypoglycemic events (and number of events) , defined as events requiring assistance of a third party, and with confirmed hypoglycemic events (and number of events) defined as events with concomitant self monitoring of blood glucose (SMBG) \\< 70 mg/dL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants That Reach Therapeutic Goal (HbA1c ≤ 7%) at Week 24 Without Any Hypoglycaemic Episode (Symptomatic or Not) and Without Any Weight Gain (Variation ≥3% Compared to Baseline)","description":"HbA1c \\<= 7% without any hypoglycaemic episode (symptomatic or not) and without any weight gain","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Dyspepsia","Urinary tract infection","Conjunctival haemorrhage","Visual impairment","Fatigue"]}}}